Literature DB >> 34240111

Midlife Blood Pressure Variability and Risk of All-Cause Mortality and Cardiovascular Events During Extended Follow-up.

Adam de Havenon1, Alen Delic1, Shadi Yaghi2, Ka-Ho Wong1, Jennifer J Majersik1, Eric Stulberg1, David Tirschwell3, Mohammad Anadani4.   

Abstract

BACKGROUND: Studies demonstrate an association between visit-to-visit blood pressure variability (BPV) and cardiovascular events and death. We aimed to determine the long-term cardiovascular and mortality effects of BPV in midlife in participants with and without cardiovascular risk factors.
METHODS: This is a post-hoc analysis of the Atherosclerosis Risk in the Community study. Long-term BPV was derived utilizing mean systolic blood pressure at Visits 1-4 (Visit 1: 1987-1989, Visit 2: 1990-1992, Visit 3: 1993-1995, Visit 4: 1996-1998). The primary outcome was mortality from Visit 4 to 2016 and secondary outcome was cardiovascular events (fatal coronary heart disease, myocardial infarction, cardiac procedure, or stroke). We fit Cox proportional hazards models and also performed the analysis in a subgroup of cardiovascular disease-free patients without prior stroke, myocardial infarction, congestive heart failure, hypertension, or diabetes.
RESULTS: We included 9,578 participants. The mean age at the beginning of follow-up was 62.9 ± 5.7 years, and mean follow-up was 14.2 ± 4.5 years. During follow-up, 3,712 (38.8%) participants died and 1,721 (n = 8,771, 19.6%) had cardiovascular events. For every SD higher in systolic residual SD (range 0-60.5 mm Hg, SD = 5.6 mm Hg), the hazard ratio for death was 1.09 (95% confidence interval [CI] 1.05-1.12) and for cardiovascular events was 1.00 (95% CI 0.95-1.05). In cardiovascular disease-free participants (n = 4,452), the corresponding hazard ratio for death was 1.12 (95% CI 1.03-1.21) and for cardiovascular events was 1.01 (95% CI 0.89-1.14).
CONCLUSION: Long-term BPV during midlife is an independent predictor of later life mortality but not cardiovascular events. © American Journal of Hypertension, Ltd 2021. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  blood pressure; death; hypertension; major adverse cardiovascular event

Mesh:

Year:  2021        PMID: 34240111      PMCID: PMC8643578          DOI: 10.1093/ajh/hpab106

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   3.080


  36 in total

1.  Visit-to-Visit Blood Pressure Variability, Coronary Atheroma Progression, and Clinical Outcomes.

Authors:  Donald Clark; Stephen J Nicholls; Julie St John; Mohamed B Elshazly; Haitham M Ahmed; Haitham Khraishah; Steven E Nissen; Rishi Puri
Journal:  JAMA Cardiol       Date:  2019-05-01       Impact factor: 14.676

2.  Ten-year risk of all-cause mortality: assessment of a risk prediction algorithm in a French general population.

Authors:  Emilie Bérard; Vanina Bongard; Dominique Arveiler; Philippe Amouyel; Aline Wagner; Jean Dallongeville; Bernadette Haas; Dominique Cottel; Jean-Bernard Ruidavets; Jean Ferrières
Journal:  Eur J Epidemiol       Date:  2010-12-28       Impact factor: 8.082

3.  Visit-to-visit blood pressure variability is related to albuminuria variability and progression in patients with type 2 diabetes.

Authors:  S Noshad; M Mousavizadeh; M Mozafari; M Nakhjavani; A Esteghamati
Journal:  J Hum Hypertens       Date:  2013-07-11       Impact factor: 3.012

4.  5 year mortality predictors in 498,103 UK Biobank participants: a prospective population-based study.

Authors:  Andrea Ganna; Erik Ingelsson
Journal:  Lancet       Date:  2015-06-03       Impact factor: 79.321

5.  Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke.

Authors:  Peter M Rothwell; Sally C Howard; Eamon Dolan; Eoin O'Brien; Joanna E Dobson; Bjorn Dahlöf; Neil R Poulter; Peter S Sever
Journal:  Lancet Neurol       Date:  2010-03-11       Impact factor: 44.182

6.  Comparison of blood pressure variability between losartan and amlodipine in essential hypertension (COMPAS-BPV).

Authors:  Jun-Won Lee; Eunhee Choi; Jung-Woo Son; Young Jin Youn; Sung-Gyun Ahn; Min-Soo Ahn; Jang-Young Kim; Seung-Hwan Lee; Junghan Yoon; Dong Ryeol Ryu; Sang-Min Park; Kyung-Soon Hong; Byung-Su Yoo
Journal:  Am J Hypertens       Date:  2020-04-08       Impact factor: 2.689

7.  Visit-to-Visit Variability of Blood Pressure Is Associated With Hospitalization and Mortality in an Unselected Adult Population.

Authors:  Marc D Basson; Marilyn G Klug; Jeffrey E Hostetter; Joshua Wynne
Journal:  Am J Hypertens       Date:  2018-09-11       Impact factor: 2.689

8.  The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Authors:  Ian M Kronish; Amy I Lynch; Suzanne Oparil; Jeff Whittle; Barry R Davis; Lara M Simpson; Marie Krousel-Wood; William C Cushman; Tara I Chang; Paul Muntner
Journal:  Hypertension       Date:  2016-05-23       Impact factor: 10.190

9.  Association of visit-to-visit blood pressure variability with the risk of all-cause mortality and cardiovascular events in general population.

Authors:  Liye Dai; Lu Song; Xiaoli Li; Yuling Yang; Xiaoming Zheng; Yuntao Wu; Chunhui Li; Hualing Zhao; Yilong Wang; Shouling Wu; Yongjun Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-02-19       Impact factor: 3.738

10.  Association of Blood Pressure Patterns in Young Adulthood With Cardiovascular Disease and Mortality in Middle Age.

Authors:  Yuichiro Yano; Jared P Reis; Cora E Lewis; Stephen Sidney; Mark J Pletcher; Kirsten Bibbins-Domingo; Ann Marie Navar; Eric D Peterson; Michael P Bancks; Hiroshi Kanegae; Samuel S Gidding; Paul Muntner; Donald M Lloyd-Jones
Journal:  JAMA Cardiol       Date:  2020-04-01       Impact factor: 14.676

View more
  1 in total

Review 1.  Association between Variability of Metabolic Risk Factors and Cardiometabolic Outcomes.

Authors:  Min Jeong Park; Kyung Mook Choi
Journal:  Diabetes Metab J       Date:  2022-01-27       Impact factor: 5.376

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.